Insmed (INSM) Gains +9% as Brinsupri Momentum Builds
Key Takeaways
- Insmed shares gained approximately 9% over the 30-day period through mid-July 2026, reflecting growing commercial traction for newly launched Brinsupri in non-cystic fibrosis bronchiectasis (NCFB).
- The stock remains well below its 52-week high of $212.75, trading near $107, as the company works to scale its respiratory franchise and narrow operating losses.
- First-quarter 2026 revenue surged 229.7% year-over-year to $305.96 million, driven primarily by Brinsupri adoption since its August 2025 FDA approval.
- Positive 12-month open-label extension data for treprostinil palmitil inhalation powder (TPIP) in pulmonary arterial hypertension, released July 16, 2026, added to pipeline momentum.
- Analyst consensus remains broadly bullish, with price targets ranging from $161 to $235, though insider selling and recent institutional repositioning warrant investor attention.
Current Market Snapshot
Insmed Incorporated (INSM) entered mid-July 2026 trading near $107 per share, up roughly 9% over the preceding 30 days. The biopharmaceutical company has experienced a volatile 12 months, with shares oscillating between a low of $90.39 and a high of $212.75. The stock currently sits below both its 200-day moving average of approximately $136 and its 50-day moving average of roughly $106, reflecting the broader correction from 2025 peaks. Despite the pullback from all-time highs, the recent upward trajectory coincides with tangible commercial execution—Brinsupri prescriptions continue to expand, and the company's pipeline is delivering incremental clinical data across pulmonary arterial hypertension and other inflammatory indications. With a market capitalization around $23.8 billion and a current ratio of 4.47, Insmed maintains ample financial flexibility to fund ongoing research and global commercial launches. I also checked this using Tickeron’s AI Trend Prediction Engine to see how momentum stacks up against peers.
Insmed (INSM) Business Overview and Competitive Position
Insmed is a global biopharmaceutical company headquartered in Bridgewater, New Jersey, dedicated to developing and commercializing therapies for patients with serious and rare diseases—with a particular emphasis on difficult-to-treat pulmonary conditions. The company's commercial portfolio features two key products: ARIKAYCE (amikacin liposome inhalation suspension), an inhaled antibiotic approved for refractory Mycobacterium avium complex (MAC) lung disease, and Brinsupri (brensocatib), a first-in-class dipeptidyl peptidase 1 (DPP1) inhibitor approved by the FDA in August 2025 as the first and only treatment for non-cystic fibrosis bronchiectasis. Brinsupri targets neutrophilic inflammation, a root cause of NCFB exacerbations, and is viewed as a potential multi-billion-dollar franchise—Insmed projects global peak sales of approximately $5 billion in the NCFB indication alone. The company also holds European Commission and UK approvals for Brinsupri and is advancing a pipeline that includes TPIP for pulmonary arterial hypertension (currently in Phase 3 PALM-PAH), brensocatib for hidradenitis suppurativa (Phase 2b CEDAR), and chronic rhinosinusitis without nasal polyps (Phase 2b BiRCh). From what I see, the focus on rare pulmonary diseases gives INSM a specialized edge in a competitive space.
Recent Developments Driving INSM
Several factors have shaped Insmed's stock trajectory over the past month. On July 16, 2026, the company reported 12-month open-label extension data for TPIP in pulmonary arterial hypertension, demonstrating mean improvement in six-minute walk distance of approximately 55 meters and a roughly 60% reduction in NT-proBNP levels across both treatment arms. The data reinforced confidence in the ongoing Phase 3 PALM-PAH registrational trial. Separately, the company maintained strong visibility at the American Thoracic Society (ATS) 2026 international conference in May, where multiple poster presentations highlighted Brinsupri's real-world symptom improvement data from the ASPEN trial.
On the commercial front, Brinsupri launch metrics remain a core focus. The drug generated $144.6 million in its first full quarter and approximately $172.7 million for full-year 2025, with roughly 4,000 prescribers and 9,000 new patient starts in Q4 2025 alone. First-quarter 2026 revenue reached $305.96 million, handily beating consensus estimates. Meanwhile, European launches commenced in the first half of 2026, and UK approval was secured in February 2026, with a Japanese regulatory submission pending.
Analyst sentiment remains favorable. Guggenheim maintained a Buy rating with a $207 price target, while RBC Capital and Jefferies reiterated Outperform and Buy ratings at $195 and $175, respectively. Wells Fargo raised its target to $161, citing oversold conditions around Brinsupri discontinuation concerns. However, insider selling activity—including transactions by CEO William Lewis and CFO Sara Bonstein executed under Rule 10b5-1 plans—and selective institutional position reductions by firms such as Simplify Asset Management have introduced mixed signals. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Trending AI Robots
As part of my ongoing research into algorithmic approaches for biotech names like INSM, I regularly review Tickeron’s Trending AI Robots page. This section highlights a curated selection of top-performing AI-powered trading bots from Tickeron’s broader ecosystem of hundreds of automated strategies covering thousands of tickers. Each bot is built with distinct parameters—including swing trading, trend following, and momentum-based approaches—operating across varied timeframes and risk profiles. The page focuses only on bots showing strong recent performance and relevance to current market conditions, which helps me quickly identify tools that align with my investment process. Exploring it has been useful for spotting strategies that complement my fundamental analysis in today’s environment.
2026 Outlook and What Investors Should Watch
Insmed's investment narrative for the remainder of 2026 hinges on several key catalysts. Brinsupri prescription trends and second-quarter revenue figures—expected in early August—will be closely scrutinized for evidence of sustained adoption and patient persistency. Discontinuation rates represent a particular area of analyst focus, as real-world persistence data could either validate or challenge the drug's multi-billion-dollar peak sales thesis. European and UK launch execution will also shape sentiment, as international markets represent substantial incremental revenue opportunities.
On the clinical side, the Phase 2b CEDAR study of brensocatib in hidradenitis suppurativa is expected to deliver interim futility analysis data in 2026, potentially opening a meaningful dermatology expansion opportunity. The Phase 3 PALM-PAH trial for TPIP remains a major value driver, with topline results anticipated to define the company's pulmonary arterial hypertension strategy. Investors should also monitor competitive dynamics—Boehringer Ingelheim's verducatib and Haisco/Chiesi's HSK31858 are advancing through Phase 3 NCFB trials—as well as broader biotech sector sentiment, macroeconomic conditions, and any regulatory developments across Insmed's key territories. While consensus analyst price targets suggest significant upside, the company's path to sustained profitability remains a central question for long-term investors. One thing that stands out is how these catalysts could influence the stock's ability to reclaim higher levels.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INSM in downward trend: price dove below 50-day moving average on September 25, 2026
INSM moved below its 50-day moving average on September 25, 2026 date and that indicates a change from an upward trend to a downward trend. In 36 of 37 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on September 17, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INSM as a result. In 64 of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
The 10-day moving average for INSM crossed bearishly below the 50-day moving average on September 30, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INSM declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 74%.
The Aroon Indicator for INSM entered a downward trend on October 09, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Indicator shows that the ticker has stayed in the oversold zone for 4 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 14 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +3.39% 3-day Advance, the price is estimated to grow further. Considering data from situations where INSM advanced for three days, in 214 of 301 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.
INSM may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 63 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.898) is normal, around the industry mean (26.780). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (23.148) is also within normal values, averaging (438.009).
The Tickeron Price Growth Rating for this company is 83 (best 1 - 100 worst), indicating slightly worse than average price growth. INSM’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a biopharmaceutical company
Industry Biotechnology
Advertisement